Hybrid LC-MS/MS, also called immunocapture or immunoaffinity LC-MS/MS, combines an affinity capture step with mass spectrometric detection. It is used to quantify antibodies, bispecifics, ADCs and other protein therapeutics when a ligand-binding assay (LBA) is not practical or not specific enough.
This article explains how the method works, when it is the better choice, its limitations, and how it is validated for regulated studies.
Only one binding reagent is needed, compared with two for a typical sandwich LBA, and detection is based on the analyte's mass rather than a second binding event.
| Situation | Why hybrid LC-MS/MS helps |
|---|---|
| No anti-idiotypic reagents yet (early development) | Generic capture plus a signature peptide from the human constant region works in animal matrices for many IgG1 and IgG4 molecules |
| ADC conjugated payload | Released payload is measured directly; with total antibody it gives the average DAR over time |
| Bispecifics and multidomain proteins | Peptides from different domains can show whether the molecule stays intact |
| Specificity concerns (cross-reactivity, soluble target, ADA) | Mass-based detection reduces some interferences; capture choice still determines whether free or total drug is measured |
| Several analytes from one sample | Multiple peptides or payload can be measured after a single capture |
A well-designed LBA is often still preferred when very high sensitivity is needed for a monoclonal antibody in human samples and good reagents exist. Many programs use both: LBA for total antibody and LC-MS/MS for payload-related analytes.
Hybrid methods used for regulated PK and toxicokinetic data are validated following ICH M10. Because they combine binding and chromatographic steps, validation addresses selectivity, specificity, calibration curve, accuracy and precision, carry-over, matrix effects, dilution linearity, stability, and incurred sample reanalysis during study sample analysis. Critical reagents, including the capture reagent and internal standard, are characterized and tracked by lot.
Hybrid LC-MS/MS methods are developed, validated and run at our GLP- and GCLP-compliant bioanalysis laboratory in Pleasanton, California on a SCIEX 7500 triple quadrupole system. For complex analytes, such as ADC payloads, catabolites or modified proteins, the high-resolution mass spectrometry team at our Natick, Massachusetts laboratory helps identify species and select signature peptides during method development.
See our generic LC-MS/MS ADC PK case study, PK assays for biologics and ADCs and strategies for ADC bioanalysis.
LBA, hybrid LC-MS/MS, or both? Discuss your molecule with Dr. Meina Liang, our Chief Scientific Officer & Head of Bioanalysis and Biomarkers
One hour at no cost with the leader who supervises our bioanalysis projects, with a CDA in place first.
A bioanalytical method that enriches a protein drug with an affinity capture reagent, digests it or releases its payload, and quantifies a signature peptide or the payload by LC-MS/MS.
When specific reagents are not yet available, when higher specificity is needed, for ADC conjugated payload, for multidomain proteins, or when several analytes should be measured from one sample.
It depends on the capture reagent. Target or anti-idiotypic capture tends to measure drug with a free binding site; generic Fc or protein A/G capture tends to measure total drug.
Yes. Methods supporting regulated PK and toxicokinetic data are validated following ICH M10 and run under GLP or GCLP as the study requires.
By measuring conjugated payload (after enzymatic release) and total antibody in the same samples; their molar ratio gives the average DAR over time.